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Abstract
The identification and development of novel and more efficient anti-inflammatory drugs for management of Cystic Fibrosis (CF) airway disease remains a 
compelling need. Sphingolipids (SLs) play an important regulatory role in CF due to their function in pulmonary infections and inflammation. Given the emerging 
importance of SLs in much pathology, novel drugs are continuously developed to selectively target different enzymes involved in SL metabolism. Iminosugars 
disclose offer exciting and innovative opportunities for therapeutic agent discovery. Miglustat, the most popular iminosugar, has an anti-inflammatory effect 
in CF models through inhibiting non-lysosomal-β-glucosidase 2 (GBA2). A small library of neoglycoconjugates with an adamantane mojety (AMP-DNJ), 
characterized by differences in the length of the alkyl chain between the iminosugar and AMP, has been synthesized from the lead iminosugar deoxynojirimycin 
(DNJ) (Ardes-Guisot, 2011). This study was hence aimed to test the effect of these AMP-DNJ derivatives on the inflammatory response to P. aeruginosa in CF 
bronchial epithelial cells. Our original findings demonstrate that these AMP-DNJ derivatives reduce IL-8 mRNA expression in CF bronchial cells infected by 
P. aeruginosa at nanomolar concentrations. The selectivity towards β glucosidase seems to be modulated by variation of the length of the chain linking the 
iminosugar and AMP, which are key motifs for the therapeutic activity of these compounds. Our results further support the use of SL metabolism modulators 
for treating CF lung inflammation, thus providing useful hints on relevant targets and chemical structures that may be regarded as starting points for a drug 
discovery campaign. 
ABBREVIATIONS
CF: Cystic Fibrosis; NSAIDs: Non-steroidal anti-inflammatory drugs; SLs: Sphingolipids; NB-DNJ: N-butyldeoxynojirimycin; 
GSL: Glycosphingolipid; GBA2: Non-lysosomal β-glucosidase 2; 
GlcCer: Glucosylceramide; AMP: Adamantane; CBE: Conduritol-B-epoxide 
INTRODUCTIONCystic Fibrosis (CF) lung disease is characterised by 
progressive chronic infection and inflammation of the airways, 
then leading to irreversible lung damage and fibrosis, which 
represent the major cause of mortality in patients with this 
condition [1]. Given the role of the inflammatory process as 
a driver of irreversible lung destruction, increasing attention 
is focused on anti-inflammatory therapies, with the aim to 
ameliorate CF lung pathology. High doses of non-steroidal anti-
inflammatory drugs (NSAIDs), particularly ibuprofen, may 
efficiently counteract inflammation. However, the long-term effects due to prolonged use of high doses NSAIDs have yet to 
be determined [2]. Therefore, the identification and development of novel and more potent anti-inflammatory drugs for CF airway 
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disease remains a compelling need.
An increasing number of studies suggest that sphingolipids 
(SLs) play an important regulatory role in CF due to their 
favourable activity in pulmonary infections and inflammation, 
thus supporting the use of modulators of SL metabolism as 
therapeutic agents for CF lung disease [3-9]. Given the emerging 
importance of SLs in respiratory disorders, novel drugs are 
being developed to selectively target different enzymes involved 
in SL metabolism. Iminosugars (i.e., sugar mimics in which the endocyclic oxygen has been replaced by nitrogen) disclose exciting and innovative opportunities for therapeutic agent 
discovery, due to their favourable oral bioavailability and 
highly specific immune modulatory and chaperoning activity 
[10]. Among the most well known iminosugars, miglustat (N-butyldeoxynojirimycin, NB-DNJ) is a US Food and Drug 
Administration (FDA)-approved and European Medicines Agency 
(EMA)-designated orally bioavailable orphan drug, used in 
Europe and USA for the treatment of type I Gaucher’s disease and other glycosphingolipid (GSL) storage diseases. We previously 
showed that miglustat has an anti-inflammatory effect in vitro and 
in vivo, and reduces the P.aeruginosa-induced immunoreactive 
ceramide expression [11,8] through inhibition of non-lysosomal-
β-glucosidase 2 (GBA2) [12]. As a glucose- and short-chain 
ceramide-mimetic, miglustat inhibits a broad array of enzymes 
involved in carbohydrate, glycoprotein and glucosylceramide 
(GlcCer) metabolism. This observation may lead to putative off-
target effects, thereby raising concerns about the efficacy of this 
treatment. Starting from the lead compound DNJ, a small library 
of adamantane neoglycoconjugates (AMP) has been prepared 
and mainly encompassing alkyl chains of various length [13]. 
The efficacy of these molecules has been already demonstrated 
for the modulation of the biological activity, especially regarding 
glycoenzyme inhibition profile and activity on the cellular 
enzymes involved in GlcCer metabolism [13]. Therefore, this 
study was planned to test the effect of this small library of AMP-
DNJ derivatives on the inflammatory response to P.aeruginosa in CF bronchial epithelial cells. 
MATERIALS AND METHODS
Cells and bacteria
CuFi-1 cells [14] (a generous gift of A. Klingelhutz, P. Karp and 
J. Zabner, University of Iowa, Iowa City; USA) are human bronchial 
epithelial cells, grown as described elsewhere [11]. Reference P. 
aeruginosa strain, PAO1, kindly provided by A. Prince (Columbia 
University, New York; USA) was grown in trypticase soy broth 
(TSB) or agar (TSA) (Difco) as described elsewhere [11]. 
Inhibitors of SL metabolism 
AMP-DNJ derivatives were synthesized as described 
elsewhere [13]. 
Inflammatory response in vitro
Cells were treated with different inhibitors or solvent alone, 
and then infected with PAO1 for 4 hours at 37oC as described 
elsewhere [11]. The inflammatory response to PAO1 infection 
was studied at transcriptional level by measuring the expression 
of the chemokine IL-8, as previously specified [8]. 
Enzymatic activity
CuFi-1 cells seeded on T25 cm2 flask were differently treated, 
scraped and pelleted. The cellular pellets were resuspended in 
water containing protease inhibitors and sonicated. An aliquot of 
cell lysate was used to detect the protein concentration by the DC 
Protein Assay (Biorad). The enzymatic activities associated with 
total cell lysates were determined using fluorigenic substrates 
as described elsewhere [15]. Aliquots of the cell homogenates 
were transferred to a 96-well microplate and enzymatic assays 
performed with three-fold replication. For GBA1 and GBA2 assay 
a pre-incubation in McIlvaine buffer (pH 6) containing 5nM of 
AMP-DNJ (which inhibits GBA2) and with 1mM of Conduritol-
B-epoxide (CBE) (which inhibits GBA1) respectively, was 
performed for 30 minutes at room temperature. 
Statistics
Results are expressed as mean ± standard error (SE). 
Comparisons between groups were performed using Student’s 
t test. Statistical significance was set at p<0.05. In order to 
calculate IC50 values, experimental data were fitted by non linear 
regression, using software “R Core Team, 2013,”R: A language 
and environment for statistical Computing”, R Foundation for 
Statistical Computing, Vienna, Austria.
RESULTS AND DISCUSSION
In this paper, we studied a small library of AMP derivatives 
(compounds #14-20) characterized by differences in the total 
length of the alkyl chain between the iminosugar and AMP. First, 
the effect of these compounds on expression of IL-8 induced by 
PAO1 infection in CuFi-1 cells was tested. Cells were treated with 
increasing doses (from 0.001 to 100 µ M) of AMP-DNJ conjugates 
or with solvent alone for 1 hour before infection. Doses higher 
than 5 µM of compound #20 were not tested, due to cellular 
toxicity. Cells were then infected with PAO1 for 4 h and the 
effect of treatment was tested by measuring the expression of 
IL-8 induced by PAO1. As shown in Figure (1), all the AMP-DNJ 
conjugates reduced PAO1-stimulated IL-8 mRNA expression in CuFi-1 cells. In order to calculate the IC50 values, experimental 
data reported in Figure (1) (panels A-G), were fitted by non-
linear regression and summarized in Table (1). IC50 and maximal 
inhibition obtained with miglustat and Genz-529648 (N- 
(5-adamantane-1-yl-methoxy) pentyl)- deoxynojirimycin) [12] 
are also reported. All AMP-DNJ derivatives herein tested were 
more effective than miglustat, with IC50 values in the nanomolar 
range. As reported in Table (1), the IC50 values were found to 
be similar to that of Genz-529648, thus underpinning that the 
addition of AMP moiety to iminosugar increases the therapeutic 
potential in terms of anti-inflammatory effect in CF bronchial cells [12]. 
Although these AMP-DNJ conjugates have been already 
evaluated in terms of glycoenzyme inhibition profiling, including 
glucosidases, galactosidases and mannosidases [13], there is 
no information concerning their effect in CF bronchial cells, 
in particular on GBA2 activity. Therefore compounds #14, 
16, 17, and 18 were tested on total β-glucosidase, GBA1 and 
GBA2 activities in cell lysates obtained from CuFi-1 cells, at 
two different concentrations: [0.5 µM] (Figure 2, panels A-C) 
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and [5 µM] (Figure 2, panels D-F). The shorter compound #14 
reduced relevantly only GBA2 (Figure 2, panels C and F), whereas 
derivatives #16, #17 and #18 impacted total β−glucosidase other 
than GBA2 (Figure 2, panels A and D) and GBA1 activity (Figure 2, 
panels B and E). These findings were more evident when CuFi-1 
cells were treated with the AMP-DNJ conjugates at the highest 
concentration (Figure 2, panels D and E), indicating that only the 
shorter analogue #14 was selective for GBA2, as it did not affect 
total β−glucosidase and GBA1 activities even when was used 
at [5µM]. The other compounds # 16, #17 and #18 completely 
inhibited GBA2 activity, even at the lower concentration, although 
they were either effective on GBA1.
Our findings demonstrate that AMP-DNJ derivatives herein 
tested exhibit interesting anti-inflammatory activity in CF bronchial cells infected by P. aeruginosa (Figure 1 and Table I). 
The selectivity towards β−glucosidase seems to be modulated 
by variation of the length of the chain linking the iminosugar 
and AMP (Figure 2). Compound #14, displaying the shortest 
spacer in this library, seems to be selective for GBA2 (Figure 2, 
panels C and F) and, even more interestingly, it does not inhibit 
ER α-glucosidases I and II [13], whereas longer derivatives, 
which were poor selective inhibitors of GBA2 at least in our 
experimental conditions, were found to be potent α-glucosidase inhibitors [13]. In addition #14 has been found to restore CFTR 
Figure 1 Effect of AMP-DNJ derivatives on IL-8 mRNA expression in CF bronchial cells infected by PAO1. CuFi-1 cells were treated with increasing 
doses (from 0.001 to 100µM) of compounds #14 (A), #15 (B), #16 (C), #17 (D), #18 (E), #19 (F), (0.001-5µM) #20 (G) or solvent alone for 1 
hour and then infected with PAO1 (50 CFU/cell) for 4 hours at 37°C. The inflammatory response was evaluated by as IL-8 mRNA expression, 
measured by Real-time qPCR and normalized on housekeeping gene β-actin. Results, expressed as % of untreated cells are mean ± standard error of 
3 independent experiments in duplicate. Comparisons between groups were performed using Student’s t test; p<0.05 (*); p<0.01 (**); p<0.001(***).
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dependent chloride transport [13]. Although Genz-529648 
seems to be more effective than #14 in reducing IL-8 production, 
at least in our experimental model, the selectivity for GBA2 and 
its effect as CFTR corrector makes #14 a compound to be further explored as an anti-inflammatory drug for CF lung inflammation, 
acting through the modulation of SL metabolism.
CONCLUSION
Our previous findings [12] support the contention that GBA2 
is involved in the inflammatory response to P. aeruginosa (Figure 
3). The results herein presented further propose the use of 
inhibitors of GBA2 activity to reduce the inflammatory response to P. aeruginosa in CF bronchial cells. This study provides a clear 
support for the development of therapeutic options for CF lung 
inflammation using iminosugars, which can be effective at even 
low doses, thus limiting potential adverse and/or toxic effects. 
In this respect, all the alkylated iminosugars herein tested 
reduced IL-8 mRNA expression in CF bronchial cells infected by 
P. aeruginosa and inhibited GBA2 activity. Notably, they were 
even more effective than miglustat, wherein needing lower 
A) B) C)
D) E) F)
Figure 2 Effect of AMP-DNJ derivatives on β-glucosidase activity in CF bronchial cells. CuFi-1 cells were treated with #14, #16, #17 and #18 [0.5µM] 
(A-C) or [5µM] (D-F) for 1 hour and β-glucosidase activity measured as described elsewhere (12). Results reported in the Figure are mean ± standard 
error of 3 independent experiments. Comparisons between groups were performed using Student’s t test; p<0.05 (*); p<0.01 (**); p<0.001(***).
Table 1: Inhibition of P.aeruginosa stimulated IL-8 mRNA expression in CuFi-1 cells.
Inhibitor IC50 CI Maximal Inhibition CI
(µM) (µM) (%) (%)
#14 0.012 0.002-0.06 43 29-57
#15 0.005 0.0001-0.23 23 18-28
#16 0.045 0.008-0.24 36 29-43
#17 0.035 0.018-0.066 40 36-44
#18 0.62 0.19-0.27 36 24-48
#19 0.007 0.003-0.016 36 32-40
#20 0.002 0.0001-0.02 28 17-39
Miglustat* 1.9 1.4-2.7 51.5 51-57
Genz-529648* 0.002 0.002-0.003 46.0 38-53IC50 values (i.e. inhibitor concentration resulting in 50% inhibition) were calculated by fitting experimental data with a non-linear regression, 
according to the formula:-log(I) = pKi + log (V-v)/v
I= inhibitor concentration; v= % inhibition; pKi= IC50; V= maximal inhibition; CI=confidence interval 95%
*(Loberto, 2014)
Central
Dechecchi et al. (2016)
Email: 
JSM Genet Genomics 3(2): 1015 (2016) 5/6
concentrations. The AMP moiety and DNJ are key motifs for the 
therapeutic potential of these iminosugars. The novelty of our 
findings is that these classes of molecules which are inhibitors of 
GBA2 activity are all effective in reducing the expression of IL-8 
in CF bronchial epithelial cells. Our results further support the 
use of modulators of SL metabolism for CF lung inflammation and 
provide useful hints on relevant targets and chemical structures 
that may be used as foundation for a drug discovery campaign. 
Efforts to develop therapeutic strategies for CF should encompass 
immune cells as well as other cell types. Because SLs are known 
to be important modulators of immune cell function [16], our 
results suggest that iminosugars, and the signalling pathways 
they modulate, merit further exploration as possible targets for 
therapeutic interventions on innate immune function aimed to 
ameliorate CF lung inflammation. 
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